TRON (Translational Oncology at the University Medical Center of the Johannes Gutenberg University Mainz), is a biopharmaceutical research organization that pursues new diagnostics and drugs for the treatment of cancer and other severe diseases with high medical need. A focus of TRON is the translation of basic research into clinical applications that promote human health.
TRON brings together the latest concepts, cutting-edge technologies and expert know-how in genomics and next-generation sequencing, bioinformatics and biostatistics, immunology, immunotherapies, and molecular biology to facilitate the development of new drugs, medical applications and techniques. TRON partners with academic institutions, biotech companies and the pharmaceutical industry, executing research with leading-edge technologies and supporting the development of innovative drugs with its unique expertise and infrastructure.
Within TRON two main research departments each address a main contemporary demand in individualized medicine. The Biomarker Development Center (BDC) researches and validates clinically relevant molecular, cellular, and serological biomarkers, while the Immunotherapy Development Center (IDC) develops immunotherapy approaches, including monoclonal antibodies, recombinant vaccines, adoptive cellular therapies and gene therapies. The two departments share technology units and labs which have been equipped with the most advanced technology platforms and which provide quality controlled services. In addition to industry collaboration TRON offers education, training and qualification of students and scientists specializing in cancer research, immunology and all aspects of translational research.